Moreover, PCSK9 inhibitor alirocumab blocked r-Pcsk9’s effect on tumor growth (Supplementary Fig. 10e), suggesting that Pcsk9 promotes tumor dependent on its binding with Ldlr. Here, LDLR is linked to neoplasm.